Literature DB >> 30690301

Benzofuran-isatin-imine hybrids tethered via different length alkyl linkers: Design, synthesis and in vitro evaluation of anti-tubercular and anti-bacterial activities as well as cytotoxicity.

Feng Gao1, Tengfei Wang2, Meixiang Gao3, Xia Zhang3, Zhuqing Liu3, ShiJia Zhao4, ZaoSheng Lv4, Jiaqi Xiao5.   

Abstract

Herein we report the design and synthesis of twenty-two novel benzofuran-isatin-imine hybrids 7a-v tethered through propylene, butylene, pentylene and hexylene, and for the evaluation of their in vitro anti-tubercular and anti-bacterial activities as well as cytotoxicity. All benzofuran-isatin-imine hybrids exhibited considerable in vitro anti-TB (MIC: <0.016-0.218 μg/mL and 0.062-14.15 μg/mL against drug-sensitive and MDR MTB, respectively) and anti-bacterial (MIC: 0.25-64 μg/mL and 0.06-16 μg/mL against Gram-positive and Gram-negative strains, respectively) activities. All of them also showed acceptable cytotoxicity towards VERO (CC50: 8-128 μg/mL). The most active hybrid 7j (MIC: <0.016, 0.062 and 0.16 μg/mL, respectively) was >4.8 and ≥ 48 folds more potent than the first line anti-TB agents RIF and INH against both drug-sensitive MTB H37Rv and MDR-TB isolates, respectively. Moreover, hybrid 7j also demonstrated promising anti-bacterial activities with MIC values of ≤1 μg/mL against the majority of the tested Gram-negative and Gram-positive pathogens, which was comparable to vancomycin (MIC: 0.5-4 μg/mL) and CPFX (MIC: 0.125-8 μg/mL) against Gram-positive bacteria, but slightly less potent than CPFX (MIC: ≤0.03-0.5 μg/mL) against Gram-negative bacteria. The results indicated that benzofuran-isatin-imine hybrids could act as candidates for the development of anti-TB and anti-bacterial agents.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti-bacterial; Anti-tubercular; Benzofuran; Hybrid compounds; Imine; Isatin; Multi-drug resistant; Structure-activity relationship

Mesh:

Substances:

Year:  2019        PMID: 30690301     DOI: 10.1016/j.ejmech.2019.01.042

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

Review 1.  A Mini Review on Isatin, an Anticancer Scaffold with Potential Activities against Neglected Tropical Diseases (NTDs).

Authors:  Shefali Chowdhary; Amandeep Arora; Vipan Kumar
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

2.  Discovery of Some Heterocyclic Molecules as Bone Morphogenetic Protein 2 (BMP-2)-Inducible Kinase Inhibitors: Virtual Screening, ADME Properties, and Molecular Docking Simulations.

Authors:  Amany Belal; Hazem Elkady; Ahmed A Al-Karmalawy; Ali H Amin; Mohammed M Ghoneim; Mohamed El-Sherbiny; Rasha Hamed Al-Serwi; Mohamed Attia Abdou; Mona H Ibrahim; Ahmed B M Mehany
Journal:  Molecules       Date:  2022-08-30       Impact factor: 4.927

Review 3.  Therapeutic Outcomes of Isatin and Its Derivatives against Multiple Diseases: Recent Developments in Drug Discovery.

Authors:  Rameshwar S Cheke; Vaishali M Patil; Sandip D Firke; Jaya P Ambhore; Iqrar A Ansari; Harun M Patel; Sachin D Shinde; Visweswara Rao Pasupuleti; Md Imtaiyaz Hassan; Mohd Adnan; Adel Kadri; Mejdi Snoussi
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.